Traws Pharma shares surge 25.74% after-hours on IND filing for influenza therapy and updated clinical results.

Traws Pharma surged 25.74% in after-hours trading following the announcement of its IND application filing for Tivoxavir Marboxil, an influenza therapy, and updated clinical results. The news, which initially drove a 19.31% intraday gain, signaled regulatory progress and positive trial updates, reinforcing investor confidence in the drug’s development potential. The IND submission marks a critical milestone in advancing the therapy to clinical trials, while the updated data likely highlighted favorable safety or efficacy outcomes. These developments, combined with the market’s response to prior intraday momentum, fueled further gains in after-hours trading. The alignment of regulatory and clinical progress with the stock’s upward movement underscores the sector’s sensitivity to therapeutic pipeline advancements.